• Sunday, Jul 03, 2022
  • Last Update : 04:24 pm

Study: Oxford-AstraZeneca Covid-19 shot less effective against South African variant

  • Published at 10:27 am February 7th, 2021
AstraZeneca
File photo: A test tube labelled "vaccine"in front of an AstraZeneca logo in this illustration taken, September 9, 2020 Reuters

Earlier, Oxford said their vaccine has similar efficacy against the British coronavirus variant as it does to the previously circulating variants

British drugmaker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of Covid-19, based on early data from a trial.

The study from South Africa’s University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.

Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others.

“In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant,” an AstraZeneca spokesman said in response to the FT report.

The newspaper said none of the more than 2,000 trial participants had been hospitalized or died.


Also read - Pfizer-BioNTech: Covid-19 vaccine works against UK, South Africa variants


“However, we have not been able to properly ascertain its effect against severe disease and hospitalization given that subjects were predominantly young healthy adults,” the AstraZeneca spokesman said.

The company said it believed its vaccine could protect against severe disease, given that the neutralizing antibody activity was equivalent to that of other Covid-19 vaccines that have demonstrated protection against severe disease.

The trial, which involved 2,026 people of whom half formed the placebo group, has not been peer-reviewed, the FT said.

While thousands of individual changes have arisen as the virus mutates into new variants, only a tiny minority are likely to be important or change the virus in an appreciable way, according to the British Medical Journal.

“Oxford University and AstraZeneca have started adapting the vaccine against this variant and will advance rapidly through clinical development so that it is ready for Autumn delivery should it be needed,” the AstraZeneca spokesman said.

On Friday, Oxford said their vaccine has similar efficacy against the British coronavirus variant as it does to the previously circulating variants.

50
Facebook 50
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail